ArticleWorld journal of diabetes2025
Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis.
Article in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting GLP-1R and IL-17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model.The Journal of clinical investigation · 2026Article
- Synergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy Expenditure.Current obesity reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBeinaglutide, a short-acting glucagon-like polypeptide-1 receptor agonist, has shown variable efficacy in weight reduction and metabolic control in randomized controlled trials (RCTs).
aimTo summarize the therapeutic effects of beinaglutide in patients with overweight/obesity with/without type 2 diabetes.
methodsRCTs involving patients receiving beinaglutide in the intervention arm and placebo or active comparator in the control arm were searched through multiple electronic databases. The change from baseline in body weight was the primary outcome; secondary outcomes included changes in body mass index (BMI), waist circumference (WC), blood pressure, glycemic parameters, lipids, and adverse events (AEs). RevMan web was used to conduct meta-analysis using random-effects models. Outcomes were presented as mean differences (MDs), odds ratios (ORs), or risk ratios (RRs) with 95% confidence intervals (95%CIs).
resultsSix RCTs (
conclusionShort-term data from RCTs suggested that beinaglutide causes modest benefits in reducing body weight, BMI, and WC, with no significant difference in glycemic and other metabolic endpoints compared to the control arm. Safety data were consistent with those of the other drugs in the glucagon-like polypeptide-1 receptor agonist class. Larger RCTs are warranted to prove the longer-term metabolic benefits of beinaglutide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.